Immune tolerance therapy for immune-driven diseases
Official title: Immune Tolerance Network
Funded at Benaroya Research Inst at Virginia Mason · NIH-11609229 · Data updated 2026-11-12
A national collaborative effort tests new immune-tolerance treatments to help people with autoimmune and allergic diseases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | February 1, 2014 |
| Project end | January 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $489,500 |
| NIH project number | 3UM1AI109565-13S2 |
| Project ID | NIH-11609229 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals with autoimmune diseases, allergies, or those awaiting or managing transplant-related immune responses who are eligible for immune-tolerance trials.
✕Less likely to help
Patients whose condition does not respond to tolerance therapies or who are not eligible for trial protocols may not benefit.
What this research studies
This grant supports multi-site clinical trials and lab studies to test therapies that teach the immune system to tolerate certain conditions. Researchers combine patient care with advanced immunology analyses to understand how treatments change cellular and genetic processes. The work aims to speed the development of safer, more effective options for autoimmune, allergic, and transplant-related diseases. The program emphasizes collaboration across many investigators and sites to accelerate breakthroughs that could benefit patients.
Why it matters
Potential benefit: If successful, the research could lead to new therapies that reduce harmful immune reactions and improve quality of life for patients with autoimmune or allergic conditions and those needing transplant tolerance.
How similar studies have gone: Previous studies in immune tolerance have shown promise, but this program seeks to advance and accelerate successful approaches across diseases.
Where this research is happening
-
Benaroya Research Inst at Virginia Mason
Seattle, United States Active
Researchers
- Principal investigator: Buckner, Jane Hoyt — Benaroya Research Inst at Virginia Mason
- Study coordinator: Buckner, Jane Hoyt
Related research
Other NIH-funded projects on the same topics.
-
T cells and the switch from pre-autoimmunity to autoimmune disease
A study following people at risk for type 1 diabetes and people with Down syndrome to understand how certain T cells may shift toward causing autoimmune disease.
-
Genetic and epigenetic control of T cell function in autoimmune disease
This grant aims to understand how genetic and epigenetic changes affect how T cells behave in autoimmune diseases to find ways to reduce harmful immune responses.
-
Immune Tolerance Network (ITN) for immune tolerance therapies across autoimmune and allergic diseases
A national network runs clinical trials to test new immune-tolerance therapies that could help people with autoimmune and allergic diseases.
-
Immune Tolerance Network for safer, more effective immune therapies
A nationwide network tests new immune therapies to help people with autoimmune diseases, allergies, and transplant patients reach better control of their immune system.
-
Immune tolerance research network for safer transplant and autoimmune therapies
A national effort tests new treatments that make the immune system tolerate transplanted organs and fight autoimmune and allergic diseases more safely.
-
Immune Tolerance Network for allergy, autoimmunity, and transplantation
A large NIH program tests new immune-tolerance therapies to help people with autoimmune diseases, allergies, and transplant patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.